Conditions: Hepatitis C Virus
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 19
Healthy volunteers: yes

Brief summary:
The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.

Detailed description:

Arms:
arm 1: Participants with severe renal impairment will receive a single dose of velpatasvir. arm 2: Participants with normal renal function will receive a single dose of velpatasvir.

Interventions: intervention 1: Velpatasvir
Intervention descriptions: intervention 1: Velpatasvir 100 mg (2 x 50 mg tablets) administered orally

Protocol document: